Aligos Therapeutics presented positive long-term data at the EASL Congress 2026 showing that pevifoscorvir sodium monotherapy reduces the cccDNA reservoir in chronic hepatitis B patients, potentially enabling functional cure. About 40% of treated HBeAg+ patients had significant reductions in HBsAg, making them eligible for further antisense oligonucleotide (ASO) therapy. The combination of pevifoscorvir sodium with ASO ALG-170675 showed additive to synergistic antiviral effects, suggesting pevifoscorvir sodium could replace current standard treatments and play a key role in functional cure regimens. Further clinical development and regulatory progress are anticipated.
Coloplast has received FDA approval for its Titan Prime inflatable penile prosthesis (IPP), a next-generation device designed to help men with severe erectile dysfunction. The device mimics a natural erection using a durable Bioflex polymer, offering...
Hydaway Digital Corp. has appointed Angelo Valentini, a cybersecurity industry veteran and current Head of Channel Sales at Check Point Software Technologies, as a strategic advisor. Valentini will support the advancement of Hydaway's RealityChek AI ...
The global wound irrigation systems market, valued at $307.87 million in 2025, is projected to reach $430.05 million by 2035 with a CAGR of 3.55%. Growth is fueled by increasing chronic wound cases, more surgeries, and rising diabetes and obesity rat...
ScottsMiracle-Gro reaffirmed its fiscal 2026 guidance, expecting low single-digit sales growth and a gross margin of at least 32%. The company reported a 1% increase in year-to-date branded consumer sales and has locked 90% of its commodities costs, ...
Ulta Beauty reported first-quarter fiscal 2026 earnings of $7.74 per share, surpassing analyst estimates of $6.86, with revenue rising 11.1% year-over-year to $3.16 billion. The company saw growth across fragrance, haircare, makeup, and skincare cate...
